Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge

Overview of attention for article published in JAMA Oncology, November 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs: 1 blog
twitter: 18 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 10 Mendeley

So far, Altmetric has seen 1 blog post.

RCT: Effect of Camrelizumab vs. placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma.

SPECIALTIES, 15 Sep 2021

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.